Trinity Biotech ADR A

Trinity Biotech is changing the ratio of its American Depositary Shares: one ADS will in future represent 600 class A common shares instead of 20, equivalent to a 1:30 reverse split. The change takes effect at the market open on Thursday; holders must submit 30 existing ADS for exchange, with processing handled by The Bank of New York Mellon. Class A common shares are not affected; no fractional new ADS will be issued—any fractions will be aggregated, sold and the net proceeds distributed. The company expects a proportional rise in the ADS price but gives no guarantee of a 30-fold price level. » More on de.investing.com

A pre-pivotal study with around 5,000 hours of wear data shows that Trinity Biotech's wearable biosensor platform CGM+ can identify nighttime false low glucose alarms caused by sensor compression. The company developed an algorithm that combines glucose measurements with heart activity, body temperature and activity data; the feature is planned to be integrated into the CGM+ solution as development advances toward a pivotal study and regulatory submission. Trinity Biotech also notes declining revenues and a sharply fallen share price, but according to analysis remains potentially undervalued. » More on de.investing.com

Trinity Biotech announced that its subsidiary Trinovium has joined the Open Compute Project as a Silver member, giving it access to working groups on liquid‑cooling technologies for AI data centers. The company says this will speed product development and validation and target hyperscaler specifications, with Trinovium using Trinity Biotech’s existing manufacturing capacity. The move marks a strategic diversification into a market MarketsandMarkets expects to grow rapidly (from $4 billion in 2026 to $27 billion by 2033), while Trinity Biotech itself has a low market capitalization, high debt and declining revenues. » More on de.investing.com